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Abstract
Background: Perturbation of DNA methylation is frequent in cancers and has emerged as an important
mechanism involved in tumorigenesis. To determine how DNA methylation is modified in the genome of primary
glioma, we used Methyl-DNA immunoprecipitation (MeDIP) and Nimblegen CpG promoter microarrays to identify
differentially DNA methylation sequences between primary glioma and normal brain tissue samples.
Methods: MeDIP-chip technology was used to investigate the whole-genome differential methylation patterns in
glioma and normal brain tissues. Subsequently, the promoter methylation status of eight candidate genes was
validated in 40 glioma samples and 4 cell lines by Sequenom’s MassARRAY system. Then, the epigenetically
regulated expression of these genes and the potential mechanisms were examined by chromatin
immunoprecipitation and quantitative real-time PCR.
Results: A total of 524 hypermethylated and 104 hypomethylated regions were identified in glioma. Among them,
216 hypermethylated and 60 hypomethylated regions were mapped to the promoters of known genes related to
a variety of important cellular processes. Eight promoter-hypermethylated genes (ANKDD1A, GAD1, HIST1H3E,
PCDHA8, PCDHA13, PHOX2B, SIX3, and SST) were confirmed in primary glioma and cell lines. Aberrant promoter
methylation and changed histone modifications were associated with their reduced expression in glioma. In
addition, we found loss of heterozygosity (LOH) at the miR-185 locus located in the 22q11.2 in glioma and
induction of miR-185 over-expression reduced global DNA methylation and induced the expression of the
promoter-hypermethylated genes in glioma cells by directly targeting the DNA methyltransferases 1.
Conclusion: These comprehensive data may provide new insights into the epigenetic pathogenesis of human
gliomas.
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Background
Aberrant DNA methylation is associated with the gen-
esis and progression of tumors [1]. Low levels of cyto-
sine methylation in the genome (genomic
hypomethylation) are accompanied by local locus-speci-
fic hypermethylation in cancer cells [2,3]. Genomic
hypomethylation can lead to genome instability and
proto-oncogene formation, which leads to their high
expression [4]. On the other hand, the local promoter
hypermethylation is usually associated with the func-
tional silencing of tumor associated genes [5]. Therefore,
cancer cells undergo massive alterations in their DNA
methylation that results in abnormal gene expression
and malignant phenotypes.
Glioma is the most frequent and devastating primary
brain tumor in adults. Aberrant DNA methylation is
associated with the development and progression of
glioma [6]. The promoter hypermethylation and epige-
netic silencing of the O6-methylguanine-DNA
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described in glioma [7-9]. The promoter hypermethyla-
tion-associated silencing of other genes involved in the
cell cycle [10], tumor suppression [11-15], DNA repair
[16,17], tumor invasion [18], and apoptosis [19] have
also been detected in malignant glioma. However, the
aberrant genomic DNA methylation in glioma is still
not fully understood.
DNA methyltransferases (DNMTs) are critical regula-
tors of the status and intensity of methylation in the
genome. Currently, three catalytically active DNMTs,
namely DNMT1, DNMT3A, and DNMT3B, have been
identified [20]. DNMT1 is the key maintenance methyl-
transferase in mammals and is responsible for both de
novo and maintenance methylation of tumor-associated
genes. DNMT3A and DNMT3B are predominately
responsible for the de novo methylation. Although the
mechanisms leading to aberrant DNA methylation
remain to be fully elucidated, increased expression of
DNMT1 and DNMT3B and decreased expression of
DNMT3A have been observed in glioblastoma [21,22],
suggesting that abnormal DNMT expression may contri-
bute to aberrant DNA methylation and gliomagenesis.
MicroRNAs (miRNA) are ~20-22 nucleotide non-coding
RNA molecules and can negatively regulate the gene
expression. MicroRNAs can bind to the 3’ untranslated
region (3’UTR) of the target mRNA, trigger mRNA degra-
dation and/or inhibit gene translation [23,24]. Growing
evidence supports that miRNAs can act as both targets
and effectors in the development of aberrant DNA methy-
lation in the genome [25,26]. Silencing miRNA in the
hypermethylation promoter of the genes occurs in various
cancers [27-29]. Meanwhile, miRNAs can regulate DNA
methylation by targeting the regulators of DNA methyla-
tion machinery [30,31]. The microRNA-185 is predicted
to bind to the 3’ UTR of DNA methyltransferases 1
(DNMT1). However, whether and how miR-185 could
regulate DNMT1 expression and affect the genomic DNA
methylation, contributing to the development of human
glioma, has not been systemically explored.
The methlyation DNA immunoprecipitation-based
chip analysis (MeDIP-chip) is a novel high-throughput
array-based method using a monoclonal antibody
against 5-methycytidine for the enrichment of the
methylated DNA fragments and then hybridizing to the
promoter and CpG islands of the entire human genome
[32]. In this study, we employed the MeDIP-chip tech-
nology to investigate the methlyation status of whole-
genome in glioma and normal brain tissues. Subse-
quently, the promoter methylation status of eight candi-
date genes was validated and the epigenetically regulated
expression of these genes and the potential mechanisms
were examined in human glioma samples. Our data
indicate that low levels of miR-185 expression are
associated the aberrant activation of DNMT1 and global
DNA hypermethylation, contributing to the develop-
ment of human glioma. More importantly, our findings
indicate that miR-185 can directly target DNMT1,
thereby leading to a reduction in global DNA methyla-
tion (GDM) and regulating the expression of the pro-
moter-hypermethylated genes in glioma cells.
Materials and methods
Tissue samples
A total of 49 primary brain glioma samples were
obtained from brain tumor patients randomly selected
from the inpatient service of Xiangya Hospital, Central
South University from 2006 to 2009. Individual patients
with glioma were diagnosed, according to the criteria of
World Health Organization (WHO), and their tumors
were graded by pathologists based on the revised classi-
fication of the WHO (2007) [33]. The samples were
snap-frozen immediately after resection and stored in
liquid nitrogen until processing. Informed consent was
obtained directly from individual patients and subject’s
relatives, and the experimental protocols were reviewed
and approved by the Institute Research Board of the
hospital. Forty glioma samples were composited of
astrocytoma (grade I, grade II, grade III), glioblastoma
multiform (grade IV) and oligoastrocytoma (grade II,
grade III) and were used for methylation analysis by
MassARRAY. Eleven brain white matter tissue samples
from non-tumor patients were also collected as controls
(six non-tumor brain samples and five epileptic brain
samples). Of them, six primary glioma samples (astrocy-
toma grade I (n = 1), astrocytoma grade II (n = 3), and
astrocytoma grade III (n = 2 ) )f r o mt h r e em a l ea n d
female patients and four non-tumor brain samples from
two male and female were studied by MeDIP-chip.
Cell lines
Human glioblastoma-derived cell lines, U251, U87,
SF126 and SF767, were obtained from the Cell Research
Institute of Peking Union Medical College (Peking,
China). U251 and U87 were maintained in DMEM sup-
plemented with 10% fetal calf serum (FCS) and standard
antibiotics; SF126 and SF767 were cultured in minimal
essential medium. All cells were cultured in a 37°C
humidified incubator supplied with 5% CO2.
To study the effect of epigenetic modulation, glioma
cell lines were treated with, or without, 5 μmol/L of 5-
aza-2’-deoxycytidine (Sigma, Aldrich) for 4 days and the
cells exposed to freshly prepared medium containing the
same concentration of drug daily.
MeDIP and microarray hybridization
The methylation status of global DNA of individual
samples was determined by MeDIP-chip using the
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protocol. Briefly, genomic DNA was extracted from indivi-
dual tissue samples and sonicated into 100-500 bp of ran-
dom fragments. After heat-denaturation, individual DNA
samples were probed with 5 μg of mouse anti-5-methylcy-
tidine monoclonal antibody (Eurogenetec, San Diego, CA,
USA) in IP buffer (0.5% NP40, 1.1% Triton X-100, 1.5 mM
EDTA, 50 mM Tris-HCl, and 150 mM NaCl) with gentle
rotation at 4°C overnight. Subsequently, the mixture of
DNA and anti-5-methylcytidine was reacted with sheep
anti-mouse IgG-conjugated magnetic beads (Bangs labora-
tories) at 4°C for 2 h. After washing, the beads were re-
suspended and the bound proteins were digested with 80
μg of proteinase-K in digestion buffer (50 mM Tris, pH
8.0, 10 mM EDTA, 0.5% SDS) at 50°C for 3 h. The
remaining DNA was extracted with phenol-chloroform
and precipitated with ethanol. The precipitated DNA was
re-suspended in 20 μlo f1 0m MT r i s - H C lp H8 . 0a n d
used in quantitative real-time PCR (qRT-PCR) for the vali-
dation of IP efficiency and for microarray hybridization.
The immunoprecipitated methylated DNA was labeled
with Cy5 fluorophore and the input genomic DNA was
labeled with Cy3 fluorophore. The labeled DNA samples
were combined and hybridized to HG18 CpG promoter
microarray 385 K (Nimblegen). After washing, the arrays
were scanned using a GenePix 4000B scanner (Nimble-
gen). Data were extracted and exported to excel using
GenePix Pro6.0.
Microarray data analysis
Raw excel data files obtained from tiling array experi-
ments were analyzed using NimbleScan™2.3 software.
The ratios of Cy5 to Cy3 signals were calculated for all
high-quality hybridization dots, normalized, and trans-
formed to Log2Ratio. One-side Kolmogorov-Smirnov
(KS) test was conducted to obtain pv a l u eand P value
(-Log10 pv a l u e ) of each probe, according to Log2Ratio
of ambient probes within 750 bp sliding window width.
Peak score was generated by interval analysis with a cut-
off value of 2, maximum gap at 500 bp, and a minimum
run with at least two consecutive probes. The regions
with peak scores were defined as methylated, and the
level of methylation was a positive correlation with peak
scores. If the methylation frequency of a region in glioma
was significantly higher than that in non-tumor brain tis-
sues, we defined the region as a hypermethylation region.
On the contrary, we defined it as a hypomethylation
region. GFF files of Log2Ratio, P value, Peak score, and
HG18 CpG Promoter Annotation data were exported to
Signalmap 1.0 software for visual analysis and review.
MassARRAY measurements of DNA methylation
The Sequenom MassARRAY platform (CapitalBio, Beij-
ing, China) was used for the quantitative analysis of
methylation. Briefly, genomic DNA was isolated from
cell lines and brain tissue samples obtained from indivi-
dual glioma patients and non-tumor subjects. The target
DNA regions were amplified by PCR using bisulfite-
modified DNA and specific primers. The PCR reactions
were carried out in a total volume of 5 μLc o n t a i n i n g1
pmol of each primer, 40 μMo fd N T P ,0 . 1u n i to fH o t
Star Taq DNA polymerase (Qiagen), 1.5 mM MgCl2,
and buffer. PCR amplifications were performed at 94°C
for 15 min and subjected to 45 cycles of 94°C for 20
seconds, 62°C for 30 seconds, and 72°C for 1 min, fol-
lowed by 72°C for 3 min. The remaining unincorporated
dNTPs were dephosphorylated by shrimp alkaline phos-
phatase (SAP; Sequenom, San Diego, CA) at 37°C for 20
min and heat inactivated. The PCR products were
directly used as template in a 7 μL transcription reac-
tion. Twenty units of T7 DNA polymerase (Epicentre,
Madison, WI) were used to incorporate either dCTP or
dTTP in the transcripts. Ribonucleotides were used at 1
mM and the dNTP substrate at 2.5 mM; other compo-
nents in the reaction were as recommended by the sup-
plier. In the same step, RNase A (Sequenom) was added
to cleave the in vitro transcripts. The mixture was then
further diluted with H2Ot oav o l u m eo f2 7μL. Condi-
tioning of the phosphate backbone prior to matrix-
assisted laser desorption/ionization time-of-flight mass
spectrometry (MALDI-TOF MS) was achieved by the
addition of 6 mg CLEAN Resin (Sequenom). Further
experimental analysis of the contents of DNA methyla-
tion was determined, as described previously [34].
Chromatin immunoprecipitation
The potential protein and DNA interactions were char-
acterized by chromatin immunoprecipitation using an
EZ ChIP™ chromatin immunoprecipitation kit, accord-
ing to the manufacturers’ instruction (Upstate, USA).
Briefly, U251, SF767, and SF126 glioma cells were cross-
linked with 1% formaldehyde for 10 min and centri-
fuged. After being washed with ice-cold PBS, the cell
pellets were lyzed in 1% SDS lysis buffer and sonicated.
The cell lysates were incubated with 5 μg of control IgG
antibody, anti-K4 trimethylated histone H3 antibody,
anti-K9 trimethylated histone H3 antibody, or anti-
acetylated histone H3 antibody (Upstate Biotechnology)
at 4°C overnight, respectively. The immunocomplex was
precipitated by protein A/G plus agarose beads. After
being washed, the immunoprecipitates were eluted with
elution buffer. The eluted immunocomplex was treated
with RNase A overnight at 65°C, and the contained pro-
teins were removed by treatment with EDTA, 1 M Tris
Cl (pH 6.5), and proteinase K at 42°C for 1 hour. The
remaining DNA was extracted using a DNA purification
k i t( Q I A G E N ,G e r m a n y )a n de l u t e di n5 0μLE l u t i o n
Reagent C. The gene promoter sequences in the
Zhang et al. Molecular Cancer 2011, 10:124
http://www.molecular-cancer.com/content/10/1/124
Page 3 of 16immunoprecipitates were amplified by PCR using the
primers in Additional File 1.
Quantitative real-time PCR
RNA was isolated from harvested cells with Trizol
reagent (Invitrogen) and then treated with DNase
(Roche) to eliminate contaminated DNA, followed by
reversely transcribing into cDNA, according to the
instructions of Promega. The relative levels of target
mRNA transcripts to control b-actin were determined
by quantitatively PCR using SYBR green pre-mixture
and specific primers (Additional file 1, Supplementary
Table 1) in a Bio-Rad IQ5 Real-Time PCR System. The
relative levels of miR-185 to control U6 snRNA were
also determined by quantitative RT-PCR using the pri-
mers in Additional File 1.
Western blotting
Western blot was performed as previously described
[35]. Protein extracts (30 μg) were resolved on 10%
SDS-polyacrylamide gels. The proteins were transferred
onto PVDF membranes, incubated with 5% skim milk at
room temperature in TTBS (20 mM Tris-HCl, pH 7.5,
500 mM NaCl, 0.1% Tween-20), and then incubated at
4°C for 12 h with rabbit polyclonal primary antibody
against DNMT1 and mouse monoclonal antibody
GAPDH from Cell Signaling Technology (Beverly, MA,
USA). DNMT1 and GAPDH antibodies were diluted
1:1000, respectively. After washed with TTBS, the mem-
branes were incubated at 37°C for 1 h with goat anti-
rabbit IgG and goat anti-mouse IgG secondary antibo-
dies diluted 1:1000 (Boster Biological Technology). The
membranes were developed using the chemiluminescent
substrate ECL detection system (Amersham) and bands
were visualized on X-ray film (Kodak).
Luciferase assays
The 53 bp of 3’UTR of the DNMT1 gene were synthe-
sized and annealed, then inserted into the Hind III
(aagctt) and Spe I (actagt) sites of pMIR-REPORT(TM)
Luciferase vector (Ambion) at downstream of the stop
codon of the gene for luciferase. The sequences were:
sense 5’-ctagtTTTATGTAGTTTTTATATGTTGTAA-
TATTTCTTCAAATAAATCTCTCCTATAAa-3’and
anti-sense 5’-agcttTTATAGGAGAGATTTATTTGAA-
GAAATATTACAACATATAAAAACTACATAAAa-3’
for DNMT1. We also generated a mutant with 4 bp
deletion (TCTC) at the potential binding sequence of
miR-185 of the 3’UTR of the DNMT1 gene. U251 cells
were co-transfected with 0.8 μgt h eg e n e r a t e df i r e f l y
Table 1 Function and pathway analysis of the promoter hypermethylated genes identified by MeDIP-chip
Term Promoter Hypermethylation Genes
Go Term
cell communication, intracellular signaling cascade, signal transduction 23 genes: SST, DIRAS3, PTAFR, KCNN3, OR10Q1, CD81, ABRA, CASP9, FYN,
MBP, OR10H5, RCVRN, GPR31, KCNMB2, TDGF1, ANKDD1A, OPN1MW,
PKP1, PCDHB13, PI4KA, HSH2D,KNDC1, KCNMB3
neurological system process, system process, synaptic transmission,
transmission of nerve impulse
21 genes: KCNMB3, CLN3, MPZ, S100P, TRPV1, DLGAP2, SIX3,
PI4KA, RCVRN, PCDHB13, OR10H5, MBP, KCNMB2, PROM1, FYN,
SYPL1, KCNN3, OR10Q1, HTR1D, SST, GAD1
negative regulation of biological process, negative regulation of
metabolic process, negative regulation of cellular process, negative
regulation of transcription, transcription repressor activity
16 genes: SST, ST18, B4GALNT2, DEDD2, GRLF1, SALL4, RASSF2, PAIP2,
TDGF1, RASSF1, CLN3, GDNF, SIX3, DKK4, TMSB4Y, CFTR
homeostatic process, chemical homeostasis, ion homeostasis, regulation
of pH, regulation of biological quality
13 genes: KCNMB3, CCKAR, CLN3, MPZ, TRPV1, CYP11B2,
RPH3AL, KCNMB2, MBP, EDNRB, DNAJC16, DEDD2, MB
brain development, generation of neurons, neuron migration 8 genes: FYN, NNAT, CCKAR, ROBO2, SIX3, CFTR, GRLF1, GDNF
cell adhesion, biological adhesion, homophilic cell adhesion, Cadherin 14 genes: FGF6, FLRT1, CLDN18, PKP1, CD300A, FERMT3, SDK1,
FBLN7,PCDHB13, ROBO2, PCDHA12, PARVB, PCDHA8, PCDHA13
ion transport, Calcium channel, cation channel activity, gated channel
activity, ion transmembrane transporter activity, transmembrane
transporter activity
10 genes: KCNMB3, TRPV1, FYN, CACNG7, KCNN3, TRPV3,
CACNG1, SLC5A11, KCNK10, KCNMB2
cell migration, cell motility, localization of cell, cellular morphogenesis
during differentiation, cellular structure morphogenesis
9 genes: SST, GDNF, ROBO2, S100P, FYN, CCKAR, TDGF1, EDNRB, CFTR
cytoskeletal protein binding, actin binding 7 genes: PARVB, ABRA, C14orf49, RPH3AL, TMSB4Y, PDE4DIP, FYN,
PHACTR3
induction of apoptosis by extracellular signals 2 genes: SST, DEDD2
KEGG_PATHWAY
Neuroactive ligand-receptor interaction 7 genes: TRPV1, EDNRB, SST, PTAFR, GH2, CCKAR, HTR1D
MAPK signaling pathway 4 genes: CACNG7, MAP2K3, CACNG1, FGF6
Wnt signaling pathway 1 genes: DKK4
Jak-STAT signaling pathway 1 genes: GH2
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dase control vector (Promega) using Lipofectamine 2000
(Invitrogen) according to the manufacturer’sp r o t o c o l .
Firefly luciferase activities were measured using the
Luciferase Assays System (Promega) 48 hours after
transfection. b-galactosidase activity was measured using
b-galactosidase Enzyme Assay System (Promega).
DNMT1 silencing by siRNA
A siRNA oligonucleotide (5’-UUUGAUGUCAGUCU-
CAUUGGG-3’)t a r g e t i n gDNMT1 was designed as
siDNMT1 and synthesized by Invitrogen. Scrambled
siRNA was used as a negative control. U251, SF126, and
SF767 glioma cells were cultured in dishes or 96-well
plates for 24 h, and transfected with siDNMT1 or con-
trol scrambled siRNA, using Lipofectamine 2000 (Invi-
trogen) for 48 h. The cells were then subjected to
further assays or to RNA and protein extraction.
GDM analysis
Genomic DNA was isolated from U251, SF126, and
SF767 glioma cells using a genomic DNA extraction kit,
according to the manufacturer’s instructions (TaKaRa).
The contents of global DNA methylation in individual
samples were determined by high performance liquid
chromatography/diode array detectors (HPLC-DAD), as
previously described [36]. Briefly, 1 mg genomic DNA
was first denatured at 100°C for 3 min and the dena-
tured DNA was treated with nuclease P1 in the presence
of 0.01 M ammonium acetate (pH 5.3) at 45°C for 2 h.
Subsequently, the DNA samples were treated with
venom phosphodiesterase I in the presence of 0.1 M
ammonium bicarbonate at 37°C for 1 h and with alka-
line phosphatase at 37°C for 1 h. The DNA samples
were characterized by a Phenomenex C18 column (250
mm × 4.6 mm, 5 μm) with ammonium formate-metha-
nol (3:7) as mobile phase at the flow rate of 1 mL/min,
the column temperature at 20°C, and UV detection
wavelength at 260 nm.
Microsatellite markers and LOH analysis of the miR-185
locus
The five polymorphic microsatellite markers on the
chromosome 22q11, including the has-miR-185, were
screened in 12 glioma specimens and their blood sam-
ples by PCR using fluorescent dye-labeled forward pri-
mer and unlabeled reverse primer (invitrogen). The
investigated markers and their chromosomal locations
are shown in Additional File 2. PCR amplifications were
performed in 10 μL of reaction volumes containing 50
ng of genomic DNA, 5 μLo fP C RP r e m i xT a g
(TaKaRa), 4 pmol of fluorescent dye-labeled forward pri-
mer, and 4 pmol of unlabeled reverse primer, according
to the manufacturers’ instruction: denaturation at 95°C
for 10 min; 18 cycles at 94°C for 30 s, 63-54°C for 30 s
(Temperature decrease 0.5°C per cycle), and 72°C for 1
min; 18 cycles at 94°C for 30 s, 54°C for 30 s, and 72°C
for 1 min; and a final extension at 72°C for 10 min.
Each 10 μL sample of the resulting PCR products was
diluted with 20 μL of H2O, and a 1.0 μL aliquot of each
diluted fluorescent-labeled PCR product was combined
with 12 μL of formamide and 0.5 μL of GeneScan™400
HD standard (Applied Biosystems). Capillary electro-
phoresis was then performed using an ABI 310 DNA
Analyzer, and the results were analyzed using GeneMap-
per software (Applied Biosystems). Allelic loss at each
microsatellite locus was considered to be present in
tumor samples’ DNA when there was at least a 65%
peak reduction at one of a pair peak compared with the
corresponding peak of normal DNA.
Statistical analysis
The levels of methylation in the specific gene of indivi-
dual samples were calculated, according to the percen-
tage of methylation in all CpG sites of the target
promoter regions. The difference in the levels of methy-
lation between glioma samples and non-tumor subjects
was analyzed by One-way ANOVA, and the difference
in the levels of gene expression and miR-185 in different
cell lines and tissue samples was analyzed by Student’s
t-test using SPSS 10.0. The potential correlation
between gene expression and methylation levels was
determined by Pearson correlation and linear regression
analysis. A p value < 0.05 was considered statistically
significant.
Results
Identification of differential methylation regions in whole
genome between primary glioma and non-tumor brain
tissues
To better understand the global changes in the levels of
DNA methylation in primary glioma, six primary glio-
mas (one astrocytoma grade I, three astrocytoma sam-
ples at grade II, and two astrocytoma samples at grade
III) from both male and female patients and four age-
and gender-matched non-tumor brain samples were
subjected to analysis of genome-wide methylation. The
methylated DNA fragments in the genome of each sam-
p l ew e r ee n r i c h e db yM e D I Pa n dt h ew h o l e - g e n o m e
interrogations were hybridized to the HG18 CpG pro-
moter microarrays that cover 28,226 CpG islands and
17,000 reference gene promoter regions of the entire
human genome.
524 hypermethylated and 104 hypomethylated
regions were indentified in the primary gliomas.
Among these regions, 361 hypermethylated and 70
hypomethylated regions were CpG islands (Figure 1A).
Intriguingly, 325 hypermethylation and 74
Zhang et al. Molecular Cancer 2011, 10:124
http://www.molecular-cancer.com/content/10/1/124
Page 5 of 16hypomethylation regions were mapped to annotated
gene regions, including the promoter, intragenic, and
downstream of genes. However, 199 hypermethylated
and 30 hypomethylated regions were mapped to the
genomic regions without any gene annotation (Figure
1B). Notably, 216 out of 325 (66.5%) of hypermethy-
lated and 60 out of 74 (81.10%) of hypomethylated
regions were mapped to the promoter regions of
known genes (Figure 1C). Some hypermethylated (53)
and hypomethylated (27) regions were mapped to both
the promoters of known genes and CpG islands (Fig-
ure 1D). Thus, there are many novel differential
methylation regions (DMRs) in the promoters, intra-
genic, downstream of known genes, and unannotated
genomic regions in primary gliomas.
The methylation status in the promoter is associated
with the regulation of gene expression and tumor devel-
opment. We further analyzed the DMRs mapped to the
gene promoters in gliomas, and the 216 hypermethy-
lated and 60 hypomethylated promoters identified by
MeDIP-chip were distributed in different loci and chro-
mosomes (Figure 1E, Additional File 3, and Additional
File 4). While the promoter-hypermethylated genes were
present predominately in the 1, 2, 3, 17, and x chromo-
somes, small numbers of the promoter-hypermethylated
genes occurred in other chromosomes. Interestingly, the
promoter-hypomethylated genes were mainly distributed
in the 1, 11, 16, 19, 20, and 22 chromosomes.
We also performed functional and pathway analysis of
these differential promoter- methylated genes using the
DAVID bioinformatics tools (Table 1 and 2) [37]. The
majority of the differential promoter-methylated genes
were clustered into several networks, and involved in a
wide variety of biological functions, including cell com-
munication, the neurological process, negative regula-
tion of the biological process, the homeostatic process,
brain development, cell adhesion, ion transport, cytoske-
letal protein binding, regulation of transcription, and
apoptosis. Some of the genes, such as events in the
MAPK, Wnt, and Jak-STAT signal pathways, were also
involved in regulating the development of tumors. In
addition, several of the promoter-hypermethylated genes
were associated with the development of human cancers
and these include GIPC2, DIRAS3, TYSPL6, EDNRB,
FYN, GDNF, RASSF1, and RASSF2 [38-43]. Apparently,
the research strategies and resulting data are valuable
for the evaluation of the significance of DMRs in
gliomas.
Validation of the methylation status in the gene
promoter of human gliomas
To confirm the results of microarray experiments, eight
candidates of the promoter-hypermethylated genes,
which were never reported in glioma, were selected
(Additional File 5) and characterized by the Sequenom’s
MassARRAY system. Significantly higher levels of
hypermethylation in the promoter regions of the genes
were observed in glioma samples, as compared with
that in normal brain tissue controls (Figure 2A). The
degrees of methylation as determined by MassARRAY
Figure 1 Genome-wide analysis of the differentially methylated regions (DMRs) in primary glioma. (A) The numbers of DMRs associated
with CpG islands (CGI). (B) The number of DMRs associated with, or without, genes. (C) The distribution of DMRs associated with genes. Most of
the identified DMRs associated with genes were mapped to gene promoters. (D) The number of DMRs in the both gene promoters and CpG
islands. (E) The chromosomal distribution of 216 promoter hypermethylated genes and 60 promoter hypomethylated genes.
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MeDIP-chip.
To further determine whether these eight gene promo-
ters were hypermethylated in other primary glioma
samples and cell lines, we subsequently characterized
the methylation status of these eight gene promoters
in 4 glioma cell lines, 40 samples from patients with
primary glioma, and 11 non-tumor brain samples by
MassARRAY (Figure 2B). The methylation levels of
seven gene promoters (ANKDD1A, GAD1, SIX3, SST,
PHOX2B, PCDHA8, and HIST1H3E) in glioma
patients and cell lines were significantly higher than
those in non-tumor controls (p < 0.01). The methyla-
tion levels in the PCDHA13 promoter in primary
glioma samples, but not in glioma cell lines, were also
significantly higher than that in non-tumor controls (p
< 0.01). A similar pattern of the promoter hypermethy-
lation was achieved by bisulfite sequencing (data not
shown). These data suggest that the hypermethylation
in the ANKDD1A, GAD1, SIX3, SST, PHOX2B,
PCDHA8, HIST1H3E, and PCDHA13 gene promoters
may be associated with the development of human
glioma. More importantly, the methylation levels of
the ANKDD1A and PHOX2B promoters tended to be
negatively correlated with age and the differentiation
grades of human glioma (Table 3). The promoters of
these two genes may be likely methylated in younger
patients with low grade of gliomas.
Epigenetic regulation of the expression of the promoter-
hypermethylated genes
To examine the role of the promoter methylation in the
regulation of gene expression, the relative levels of
mRNA transcripts of these eight promoter-hypermethy-
lated genes in several primary glioma and non-tumor
brain samples were determined by quantitative RT-PCR.
The relative levels of these gene mRNA transcripts were
slightly lower in primary glioma tissues than that in
non-tumor tissues although it was not significant (Figure
3A). Furthermore, treatment with demethylating agent
of 5-aza-2’-deoxycytidine significantly up-regulated the
expression of those promoter-hypermethylated genes in
U251, SF767, and SF126 cells (p < 0.05). However, treat-
ment with 5-aza-2’-deoxycytidine failed to modulate the
expression of SST and SIX3 that were not the promo-
ter-hypermethylated genes in SF126, the PCDHA13 in
U251 and SF126, and the PCDHA8 in SF767 cells (Fig-
ure 3B). In addition, the expression levels of those pro-
moter-hypermethylated genes were inversely associated
with the degrees of their promoter methylation in pri-
mary glioma samples (Figure 3 C ) .T h e s ed a t ai n d i c a t e
that hypermethylation in the gene promoters down-reg-
ulates the expression of these genes, which may contri-
butes to the development of glioma in Chinese patients.
Because there are cross-talks between DNA methyla-
tion and histone modification in the regulation of gene
expression, we characterized the binding of different his-
tone markers, H3Ac (histone H3 acetylation), H3K4me3
(trimethyl-histone H3 lys4), and H3K9me3 (trimethyl-
histone H3 lys9) around the promoter of those genes in
U251, SF767, and SF126 cell lines by CHIP. We found
that high levels of H3K9me3, but not H3Ac and
H3K4me3, bound to the promoter regions of these
genes when their promoters were hypermethylated in
glioma cells. In contrast, H3Ac and H3K4me3, not
H3K9me3 bound to their promoters when they were
not methylated in glioma cells. Interestingly, treatment
with 5-aza-2’-deoxycytidine decreased H3K9me3, but
increased H3Ac and H3K4me3 binding to these gene
promoter regions (Figure 3D). Apparently,
Table 2 Function and pathway analysis of the promoter hypomethylated genes identified by MeDIP-chip
Term Promoter Hypomethylation Genes
Go Term
signal transduction, cell communication 14 genes:OR10G4, BAD, C9, OR51S1, CCRL2, OR8A1, SFN, ABR, OR1L6, FKBP8,
DRD4, SORBS1, GP1BB, MLNR
protein metabolic process, cellular metabolic process, biopolymer
metabolic process
11 genes: CPEB1, C9, NRBP2, PSMF1, OR51S1, KLHL21, FKBP8, TUBB4Q,
PRSS33, FUT5, TUBB8
transport, ion channel activity, metal ion transport, cation transport 10 genes:ACCN1, ABCC12, MFSD3, SLC28A1, SLC5A9, SLC2A9, KCNK4,
TUBB4Q, TUBB8, SORBS1
hydrolase activity, serine hydrolase activity 5 genes:ABCC12, OR51S1, TUBB4Q, PRSS33, TUBB8
regulation of gene expression,regulation of transcription,DNA binding,
transcription factor activity
5 genes: CPEB1,TOX2, LMO3, PHF13, NAT14
nervous system development, system development, organ
development
3 genes: IGSF8, ACCN1, ABR
apoptotic program, induction of apoptosis, cell death 3 genes: BAD, SFN, C9
KEGG_PATHWAY
Neuroactive ligand-receptor interaction 3 genes: SCT, MLNR, DRD4
Insulin signaling pathway 2 genes: BAD, SORBS1
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Page 7 of 16Figure 2 MassARRAY analysis of methylation in primary gliomas. (A) The levels of promoter methylation in the hypermethylated genes
identified by MeDIP-chip. MassARRAY assay were performed using gDNA from samples screened by microarray. Different colors of circles mark
the position of CpG dinucleotides within the sequence (straight line) and the levels of methylation. Gray circles represent the unanalyzed CpG
sites. The ruler on the top of each gene sequence indicates the base pair position within the sequence on the top and the positions of the CpG
sites at the bottom. For all tested genes, significant hypermethylation in the promoter regions were observed in glioma samples compared with
non-tumor controls. T1, T2, T3, T4, T5, and T6 were glioma samples; N1, N2, N3, and N5 were age- and gender-matched non-tumor brain
samples. Glioma samples and non-tumor control samples were simultaneously analyzed. (B) The methylation levels of 8 selected genes identified
by MeDIP-chip in non-tumor controls, primary glioma patients and glioma cell lines. DNA methylation was analyzed by MassARRAY assay. The
name of each gene is shown in the upper part of each panel. N represents the number of cases studied for each gene and each group. Each
panel represents the results of an individual gene indicated in the upper of each graph.
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Page 8 of 16hypermethylation in the promoters of these genes is
associated with the modulation of histone and chroma-
tin structure, and regulation of gene expression in
glioma cells.
Loss of heterozygosity at the miR-185 locus located in
the 22q11.2 in glioma
Previously studies have reported that microRNA-185
expression is down-regulated in glioma [44,45]. However,
the mechanism underlying down-regulated miRNA-185
expression in glioma is uncovered. MiR-185 is located in
the 22q11 chromosome region and loss of heterozygosity
(LOH) is observed in several types of cancers [46,47].
Whether the miR-185 locus in the 22q11.2 in glioma
could be subjected to the LOH in glioma is still unknown.
Therefore, we performed LOH analysis using 5 microsatel-
lite markers spanning the 22q11 (Additional file 2, Supple-
mentary Table 2). The partial results of LOH analysis
spanning the 22q11 are shown in Figure 4. We observed
five out of 12 cases with LOH in the 22q11.21 (D22S446),
four in the 22q11.22 (D22S686), and six in the 22q11.23
(D22S925), but no single one in the 22q11.1 region
(D22S420), respectively. In addition, we detected three
cases with LOH in the 22q12.1 (D22S315).
DNTM1 is the target of miR-185
T h eD N M T 1h a sb e e nt h o u g h tt ob eap u t a t i v et a r g e to f
miR-185 [48] (Figure 5A). To demonstrate this in glioma
cells, the DNMT1 complementary sequence or the mutant
with a deletion of 4 nucleotides (UCUC) for the predicted
binding of miR-185 were cloned downstream of the firefly
luciferase gene. U251 cells were co-transfected with the
wild or mutated construct, together with miR-185 or
scrambled oligonucleotide for 24 h, and luciferase activ-
ities in those cells were measured. As shown in Figure 5B,
significantly reduced levels of luciferase activities were
detected in the cells transfected with the DNMT1 comple-
mentary sequences and miR-185, but not in the cells with
the mutant sequence and miR-185, indicating that the
DNMT1 complementary sequence contained the binding
site for miR-185. Furthermore, transfection with miR-185
significantly reduced the levels of DNMT1 mRNA tran-
scripts and protein expression in glioma cells (Figure 5C
and 5D), but did not affect the expression of DNMT3A
and DNMT3B (data not shown). More importantly, higher
levels of DNMT1 mRNA transcripts, but lower levels of
miR-185 were detected in primary glioma tissues, as com-
pared with that in non-tumor brain tissues (Figure 5E, F).
Collectively, these data indicate that the down-regulated
miR-185 expression is related to high levels of DNMT1
expression, which may be associated the development of
glioma and support the notion that miR-185 directly tar-
gets DMNT1 mRNA, thereby regulating the expression of
DNMT1 in glioma cells.
Over-expression of miR-185 reduces global DNA
methylation and induces the expression of the promoter-
hypermethylated genes
Given that low levels of miR-185 were associated with
higher levels of DNMT1, a key factor for the
Table 3 The methylation of the gene promoters in glioma patients and their clinical characteristics
Variable Methylation n (%)
ANKDD1A GAD1 HIST1H3E PCDHA8 PCDHA13 PHOX2B SIX3 SST
Sex
Male 18 (64.3) 15 (53.6) 25 (89.3) 13 (65.0) 20 (76.9) 19 (67.9) 19 (67.9) 27 (96.4)
Female 11 (91.7) 9 (75.0) 9 (75.0) 7 (70.0) 9 (75.0) 10 (83.3) 10 (83.3) 11 (91.7)
p-vablue 0.076 0.205 0.246 0.784 0.897 0.315 0.315 0.527
Age
< 45 y 18 (90.0) 13 (65.0) 17 (85.0) 12 (60.0) 17 (85.0) 18 (90.0) 14 (70.0) 19 (95.00
≥45 y 11 (55.0) 11 (55.0) 17 (85.0) 8 (40.0) 12 (60.0) 11(55.0) 15 (75.0) 19 (95.0)
p-vablue 0.013 * 0.519 1.000 0.121 0.077 0.013 * 0.723 1.000
Differentiation
Grade I-II 20 (90.9) 16 (72.7) 19 (86.4) 14 (63.6) 18 (81.8) 19 (86.4) 18 (81.8) 22 (100.0)
Grade III-IV 9 (50.0) 8 (44.4) 15 (83.3) 6 (54.5) 11 (68.8) 10 (55.6) 11 (68.8) 16 (88.9)
p-vablue 0.004 ** 0.069 0.789 0.425 0.350 0.030 * 0.145 0.109
Tumor type
A 22 (73.3) 18 (60.0) 27 (90.0) 15 (68.2) 22 (73.3) 23 (76.7) 20 (66.7) 29 (96.7)
GBM 3 (50.0) 3 (50.0) 4 (66.7) 2 (50.0) 4 (100.0) 3 (50.0) 5 (83.3) 5 (83.3)
OA 4 (100.0) 3 (75.0) 3 (75.0) 3 (75.0) 3 (75.0) 3 (75.0) 4 (100.0) 4 (100.0)
p-vablue 0.217 0.732 0.289 0.723 0.498 0.407 0.304 0.349
p-values from Chi-square test, *p-value < 0.05, ** p-value < 0.005.
A, Astrocytoma; GBM, Glioblastoma multiforme; OA, Oligoastrocytoma
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Page 9 of 16Figure 3 The expression of the promoter-hypermethylated genes was regulated epigenetically in glioma.( A )T h ee x p r e s s i o no ft h e
promoter-hypermethylated genes in primary gliomas (n = 5) and non-tumor brain tissue samples (n = 5) was detected by quantitative RT-PCR.
Data shown are mean value of individuals for each gene from three independent experiments. (B) The expression of the promoter
hypermethylated genes in the 5-aza-2’-deoxycytidine-treated glioma cells. Data are expressed as mean% ± SEM of each group of cells for the
indicated gene from three separate experiments. *p< 0.05 vs. control. (C) Correlation analysis of the levels of gene promoter methylation with its
mRNA expression. The expression was analyzed with real time PCR, while the contents of promoter methylation in primary glioma samples were
determined massarrays (n = 22-31 per group). Data shown are mean value of individual samples. (D) CHIP-PCR analysis for histone marks H3Ac
(histone H3 acetylation), H3K4me3 (trimethyl-histone H3 lys4), and H3K9me3(trimethyl-histone H3 lys9) in the promoter-hypermethylated genes.
U251, SF767, and SF126 cells were untreated or treated with 5-aza-2’-deoxycytidine. Input represents amplification from 1% chromatin before
immunoprecipitation. IgG represents negative controls immunoprecipitated by normal rabbit serum. H3Ac, immunoprecipitated by rabbit anti-
acytyl-H3; H3K4me3, immunoprecipitated by rabbit anti-trimethyl-H3(lys4); H3K9me3, immunoprecipitated by rabbit anti-trimethyl-H3(lys9).
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Page 10 of 16maintenance of global DNA methylation in mammal
cells, we further investigated whether the enforced
expression of miR-185 could functionally modulate
DNA hypermethylation in glioma cells. U251, SF126,
and SF767 cells were transfected with miR-185 mimics,
scrambled oligonucleotides, si-DNMT1 sequence, or
control siSCR, respectively, and the status of GDM was
measured by HPLC-DAD. Transfection with miR-185
Figure 4 Microsatellite analysis of the miR-185 locus in 22q11.2 in glioma and paired blood samples. (A) LOH analysis at D22S420,
22q11.1. (B) LOH at D22S446, 22q11.21. (C) LOH at D22S686, 22q11.22. (D) LOH at D22S925, 22q11.23. (E) LOH at D22S315, 22q12.1. Each peak
has a box that provides the fragment size and peak height (upper and lower labels, respectively). The arrow indicates the allele loss.
Figure 5 MicroRNA-185 targets DNMT1 mRNA at the 3’-UTR.( A )S c h e m ao ft h ef i r e f l yl u c i f e r a s ereporter constructs for the DNMT1,
indicating the interaction sites between miR-185 and the 3’-UTRs of the DNMT1. (B) Luciferase activities. U251 cells were co-transfected with
firefly luciferase constructs containing the DNMT1 wild-type or mutated 3-UTRs and miR-185 or scrambled oligonucleotides, respectively. The
firefly luciferase activities were measured and normalized to b-galactosidase activity. Data are expressed as mean ± SD of relative levels of
luciferase activity of each group of cells from three independent experiments. (C) Quantitative RT-PCR analysis of DNMT1 expression. Glioma cells
were transfected with miR-185, si-DNMT1 or controls for 48 h. The levels of DMNT1 mRNA transcripts were determined by Real time PCR. Data
are expressed as mean ± SD of each group of cells from three independent experiments. (D) Western blot analysis of DNMT1 protein. The levels
of DNMT1 expression in the transfected cells described above were characterized by Western blot assays. Data shown are representative images
of each group of cells from three separate experiments. (E) The levels of DNMT1 mRNA transcripts in normal brain tissue and primary gliomas.
(F) The levels of miR-185 expression in normal brain tissue and primary gliomas. Data are expressed as mean ± SD of each group of samples
from three separate experiments. Then indicates the sample size of each group. *p< 0.05 vs. control.
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Page 11 of 16mimics, like with siDNMT, reduced the ratio of GDM
by 20-30% in U251 cells, as compared with that in the
controls (Figure 6A). Further analysis of the promoter-
hypermethylated genes revealed that transfection with
miR-185 mimics significantly reduced the frequency of
methylation in these gene promoters (Figure 6B),
accompanied by elevating the relative levels of mRNA
transcripts of those genes in the cells (Figure 6C). For
example, U251 cells displayed relatively higher methyla-
tion in the PCDHA8, ANKDD1A, GAD1, HIST1H3E,
PHOX2B, SIX3, and SST genes, and transfection of
U251 with miR-185 reduced the methylation levels of
these gene promoters and increased the expression
levels of these genes. Furthermore, SF126 cells had
higher methylation in the PCDHA8, ANKDD1A, GAD1,
HIST1H3E and PHOX2B, but lower methylation in the
PCDHA13, SIX3, and SST genes, and transfection of the
cells with miR-185 only changed the methylation and
expression levels of the PCDHA8, ANKDD1A, GAD1,
HIST1H3E, and PHOX2B genes, but did not affect the
low methylated PCDHA13, SIX3, and SST genes.
Apparently, the modulation effects of miR-185 were
Figure 6 MicroRNA-185 reduces the levels of GDM and induces the expression of the promoter-hypermethylated genes.( A )O v e r -
expression of miR-185 reduced the levels of GDM in glioma cell lines. U251, SF126, and SF767 cells were transfected with miR-185 mimics (miR-
185M), si-DNMT1, or controls for 48 h and the levels of GDM were determined by HPLC-DAD. Data are expressed as mean ± SD of the relative
levels of GDM in each group of cells from three separate experiments. (B) The levels of promoter methylation in the promoter-hypermethylated
genes in glioma cell lines. The indicated cells were transfected with miR-185 mimics or control, and the contents of promoter methylation were
characterized by MassARRAY system. Data are expressed mean % of the methylated promoters in the indicated genes in those cells. The levels
of promoter methylation in these genes were similar to that in unmanipulated cells (data not shown). (C) Quantitative RT-PCR analysis of the
relative levels of each gene expression in the indicated cells after transfection with miR-185 mimics, si-DNMT1, or control for 48 h. Data are
expressed as mean ± SD of the relative levels of the indicated gene in different cells from three independent experiments. *p< 0.05 vs. control
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Page 12 of 16dependent on the methylation status of individual gene
promoters in each cell line.
Discussion
In this study, we employed the genome-wide CpG promo-
ter microarrays and MeDIP, a sensitive method, to identify
the differentially methylated regions in human glioma vs.
non-tumor brain tissues. We found numerous differential
methylation regions, some of which were validated in a
cohort of glioma samples by the Sequenom’s MassARRAY
system. Hence, the MeDIP-chip platform is both efficient
and effective. On the other hand, we had to admit that the
data were some limitations because our MeDIP-chip study
was based on very small number samples.
We found 524 hyermethylated and 104 hypomethy-
lated regions in glioma. Among them, 216 hypermethy-
lated and 60 hypomethylated regions were mapped to
the gene promoters, suggesting that the methylation sta-
tus may regulate the transcription of these genes. Func-
tional analysis revealed that these promoter-
hypermethylated and hypomethylated genes were
involved in the regulation of transcription, cell commu-
nication, the neurological process, apoptosis, the biologi-
cal process, the homeostatic process, brain development,
cell adhesion, ion transport, and cytoskeletal protein
binding. Several of the promoter hypermethylated genes
have already been reported in other human cancers,
suggesting that they contribute to the tumorigenesis
[37-42]. Notably, many of them are novel methylation-
regulated genes that have not been indentified pre-
viously in human glioma and other malignancies.
Apparently, these findings may help in studying the
molecular mechanisms underlying the glioma
development.
Growing evidence indicates that DNA methylation in
the promoter of a gene in cancers seems to be in a non-
random fashion and the methylation patterns vary,
dependent on cell or tumor types, subtypes within the
same category of tumors [49]. In addition to the glioma-
specific methylation patterns, we identified genomic hot-
spots, which harbor an abundance of the methylated
promoter regions. In particular, we found that the
methylation hotspots contained the promoter-hyper-
methylated genes predominantly on 1, 2, 3, 17, and ×
chromosomes. A previous study had reported that the
methylation hotspots are identified on chromosome 19
in acute lymphoblastic leukemia (ALL) cells [50]. Appar-
ently, the methylation prefers certain regions of genome
and these regions are varying in different types of
tumors. However, the mechanisms by which various
regions of genome are methylated in different types of
tumors remain to be further investigated.
We found that the promoters of the ANKDD1A,
GAD1, HIST1H3E, PCDHA8, PCDHA13, PHOX2B,
SST, and SIX3 genes were hypermethylated in glioma.
This is the first report on the promoter hypermethyla-
tion in glioma, although the methylation of some of
these genes has been reported in other types of caners
[51-54]. The ANKDD1A, ankyrin repeat, and death
domain-containing protein 1A contain 4 ankyrin repeats
that can mediate protein-protein interactions in very
diverse families of proteins with apoptosis-related death
domains. The ANKRD15 acts as a candidate tumor sup-
pressor in the development of renal cell carcinoma [55].
Given that the hypermethylation of the ANKDD1A pro-
moter occurred predominantly in low grades of glioma,
it is possible that the ANKDD1A may also function to
be a suppressor in human glioma and inhibit the devel-
opment of glioma at the early stage. The glutamate dec-
arboxylase 1 (GAD1) encodes glutmatic acid
decarboxylase that is responsible for catalyzing L-gluta-
mic acid into gamma-aminobutyric acid, an inhibitory
neurotransmitter. The promoter methylation of the
G A D 1c a ni n h i b i tt h ee x p r e s s i o no fG A D 1i ns c h i z o -
p h r e n i a[ 5 6 ] .H I S T 1 H 3 E ,am e m b e ro ft h eh i s t o n eH 3
family, can interact with linker DNA between nucleo-
somes and functions in the compaction of chromatin
into higher order of structures. This protein is differen-
tially expressed in the temporal lobe of patients with
schizophrenia [57]. PCDHA8 and PCDHA13 are mem-
bers of the protocadherin alpha family. These neural
cadherin-like cell adhesion proteins are integral plasma
membrane proteins that can play a critical role in the
establishment and function of specific cell-cell connec-
tions in the brain. The protocadherin-gamma subfamily
A11 (PCDH-gamma-A11) gene is hypermethylated in
astrocytomas [18]. The inactivation of this cell-cell con-
tact molecule may promote the invasiveness of astrocy-
toma cells. The PHOX2B (paired-like homeobox 2b), a
member of the paired family of homeobox, encodes the
DNA-associated protein in the nucleus, which functions
as a transcription factor involved in the development of
major noradrenergic neurons and the determination of
neurotransmitter phenotype. PHOX2B can also enhance
the second messenger-mediated activation of the dopa-
mine beta-hydrolase, c-fos promoters, and several
enhancers, including cyclic AMP-response element and
serum-response element. Aberrant methylation of the
PHOX2B promoter region accounts for 12.9% of human
neuroblastoma cell lines [51]. SST (somatostatin) is
expressed throughout the body and can inhibit the
release of numerous secondary hormones by binding to
the high-affinity G-protein-coupled somatostatin recep-
tors. Somatostatin also regulates the neurotransmission
rates in the central nervous system and proliferation of
both normal and tumorigenic cells. Recently, SST pro-
moter methylation has been found in various cancers,
including gastric cancer, cervical cancer and colon
Zhang et al. Molecular Cancer 2011, 10:124
http://www.molecular-cancer.com/content/10/1/124
Page 13 of 16cancer [52,53,58]. SIX3 (SIX homeobox 3) is a member
of the sine oculis homeobox transcription factor family.
SIX3 regulates the transcriptional activity of the orphan
nuclear receptor NOR-1 (NR4A3), which regulates the
survival of cells, and acts as a part of the EWS/NOR-1
fusion protein, implicating the oncogenesis of human
extraskeletal myxoid chondrosarcoma (EMC) [59].
Together, these novel genes with the hypermethylated
promoters in glioma may contribute to the initiation
and progression of glioma and potentially serve as a bio-
marker for the prognosis of human glioma.
In addition, we found that the percentages of promo-
ter methylation in the ANKDD1A and PHOX2B, but
n o tt h eG A D 1 ,H I S T 1 H 3 E ,P C D H A 8 ,P C D H A 1 3 ,S I X 3
and SST, were associated negatively with the differentia-
tion degrees of human gliomas. These data suggest that
ANKDD1A and PHOX2B may play an important role in
regulating the early development of glioma and serve as
a biomarker for early diagnosis. The GAD1, HIST1H3E,
P C D H A 8 ,P C D H A 1 3 ,S I X 3a n dS S Tm a yr e g u l a t et h e
progression of glioma.
DNA methylation in the promoters has been impli-
cated in the down-regulation of gene expression, possi-
bly through the formation of an altered chromatin
structure that is resistant to transcription initiation
[5,60]. Our study found that the expression of these
eight promoter-hypermethylated genes was significantly
down-regulated in glioma samples, as compared with
that in non-tumor brain samples. More importantly, the
contents of promoter methyla t i o ni nt h e s eg e n e sw e r e
inversely correlated with the expression levels of these
genes in glioma. Furthermore, treatment with 5-aza-2’-
deoxycytidine re-activated the expression of promoter-
hyermethylated genes in glioma cells in vitro.N o t a b l y ,
the DNA methylation is associated with the histone
modification, contributing to the gene regulation and to
the establishment and maintenance of chromosomal
domains. Indeed, we found that the H3K9me3 was
enriched, while the H3 acetylation and H3K4me3 were
down-regulated in the promoter-hypermethylated genes
of glioma cells. Treatment with 5-aza-2’-deoxycytidine
reduced the levels of H3K9me3, but increased the H3
acetylation and H3K4me3 in the promoter region of
these genes. These data suggest that the H3K9me3 is
directly associated with the promoter methylation, while
the H3 acetylation and the 3mK4H3 is inversely related
to the promoter methylation in glioma cells.
Deletion of genomic interval encompassing miR-185
(22q11.2) is an extremely frequent event in diverse types
of cancers [46,47]. The miR-185 can induce cell cycle
arrest in human non-small cell lung cancer [61]. In this
study, we found that the expression of miR-185 was sig-
nificantly down-regulated in glioma, as compared with
that in non-tumor brain tissues. Moreover, the LOH
status was found at the miR-185 locus located in the
22q11.2. Thus, the reduced levels of miR-185 expression
may be associated with the loss of 22q11.2 in glioma.
T h e s ed a t as u p p o r tt h a tt h el o s so fm i R - 1 8 5i sa l s oa
frequent event in glioma and suggest that loss of miR-
185 may contribute to the development of human
glioma.
Furthermore, we also characterized the role of miR-
185 in the regulation of DNA methylation in glioma.
We found that transfection with miR-185 and the
DNMT1 complementary sequence, but not the mutant
with deletion of the miR-185 binding sequence, dramati-
cally reduced luciferase activity in glioma cells, and the
levels of DNMT1 expression were inversely correlated
with the levels of miR-185 expression in gliomas. In
addition, over-expression of miR-185 re-activated the
expression of the promoter-hypermethylated genes in
glioma cells. These data indicated that miR-185 directly
interacted with the DNMT1 and the lower levels of
miR-185 expression promoted the abnormal expression
of DNMT1 in glioma. Given that DNMT1 is a major
player in DNA methylation, higher levels of DNMT1
expression should be responsible for the intensive
methylation of these gene promoters, which down-regu-
late the expression of these genes and contribute to the
development and progression o fg l i o m a .T h e r e f o r e ,t h e
down-regulated expression of miR-185 and up-regulated
expression of DNMT1 contribute to aberrant DNA
methylation and in turn to gliomagenesis.
Conclusions
In summary, we identified aberrant methylation in glioma
by MeDIP-chip and found that eight novel genes were epi-
genetically regulated by DNA methylation in glioma. Our
data indicated that miR-185 directly interacted with the
DNMT1 and the lower levels of miR-185 expression in
glioma may be one of the reasons for the abnormal
expression of DNMT1, which leads to aberrant DNA
methylation, contributing to the development of human
glioma. Apparently, our findings may provide new insights
into understanding the pathogenesis of glioma.
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Additional File 1: The sequences of the primers.
Additional File 2: Characteristics of polymorphic loci at the 16q22
region.
Additional File 3: Chromosomal localization of 216 promoter
hypermethylated genes identified by MeDIP-chip. The top number
indicates chromosome and bottom number indicates the promoter
hypermethylated genes identified in each chromosome. The gene names
are indicated beside each hypermethylated locus.
Additional File 4: Chromosomal localization of 60 promoter
hypomethylated genes identified by MeDIP-chip. The top number
indicates chromosome and bottom number indicates the promoter
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are indicated beside each hypomethylated locus.
Additional File 5: Examples of 8 promoter hypermethylated genes
methylation array profiles. The green boxes represent normal brain
white matter samples (N1, N2, N3, and N5). The red boxes represent the
glioma primary samples (T1, T2, T3, T4, T5, and T6). The black bars
indicate the regions analyzed by MassARRAY assay.
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